Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramucirumab - Eli Lilly and Company

Next Previous
Drug Profile

Ramucirumab - Eli Lilly and Company

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza; Xiranze

Latest Information Update: 18 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Basilea Pharmaceutica; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Adenocarcinoma; Pancreatic cancer; Soft tissue sarcoma
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 18 Jun 2026 3933981: KDM, Dev tab and HE updated; Clinical data added; request sent for creation of ctp once created will add the data in ct profile as well
  • 23 Jan 2026 Eli Lilly and Company completes the phase I/II CAMPFIRE trial in Soft tissue sarcoma (In adolescents, In children, In infants, In adults, Second-line therapy or greater, Recurrent) in USA, Belgium, France, Italy, Japan, Spain, United Kingdom, Netherlands, Germany, Australia (IV) (NCT04145349) (CTIS2018-004242-42)
  • 10 Jan 2026 Efficacy and adverse events data from the phase II RAMIEL trial in Gastric cancer presented at the 2026 Gastrointestinal Cancers Symposium (ASCO-GI-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top